Search Results - "Cassingena, A"

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer by Barault, L., Amatu, A., Bleeker, F.E., Moutinho, C., Falcomatà, C., Fiano, V., Cassingena, A., Siravegna, G., Milione, M., Cassoni, P., De Braud, F., Rudà, R., Soffietti, R., Venesio, T., Bardelli, A., Wesseling, P., de Witt Hamer, P., Pietrantonio, F., Siena, S., Esteller, M., Sartore-Bianchi, A., Di Nicolantonio, F.

“…O6-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or…”
Get full text

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer by Amatu, A., Barault, L., Moutinho, C., Cassingena, A., Bencardino, K., Ghezzi, S., Palmeri, L., Bonazzina, E., Tosi, F., Ricotta, R., Cipani, T., Crivori, P., Gatto, R., Chirico, G., Marrapese, G., Truini, M., Bardelli, A., Esteller, M., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S.

“…Objective response to dacarbazine, the intravenous form of temozolomide (TMZ), in metastatic colorectal cancer (mCRC) is confined to tumors harboring…”
Get full text

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor by Siravegna, G, Sartore-Bianchi, A, Mussolin, B, Cassingena, A, Amatu, A, Novara, L, Buscarino, M, Corti, G, Crisafulli, G, Bartolini, A, Tosi, F, Erlander, M, Di Nicolantonio, F, Siena, S, Bardelli, A

“…Monitoring response and resistance to kinase inhibitors is essential to precision cancer medicine, and is usually investigated by molecular profiling of a…”
Get full text

54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients by Barault, L, Amatu, A, Bleeker, F.E, Moutinho, C, Cassingena, A, Tosi, F, Venesio, T, Esteller, M, Bardelli, A, Siena, S, Sartore-Bianchi, A, Di Nicolantonio, F

Get full text

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer by Sartore-Bianchi, A, Bencardino, K, Cassingena, A, Venturini, F, Funaioli, C, Cipani, T, Amatu, A, Pietrogiovanna, L, Schiavo, R, Di Nicolantonio, F, Artale, S, Bardelli, A, Siena, S

“…SUMMARY Metastatic colorectal cancer (mCRC) patients carrying KRAS mutated tumors do not benefit from epidermal growth factor receptor (EGFR)-targeted…”
Get full text

Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor by Siravegna, G., Sartore-Bianchi, A., Mussolin, B., Cassingena, A., Amatu, A., Novara, L., Buscarino, M., Corti, G., Crisafulli, G., Bartolini, A., Tosi, F., Erlander, M., Di Nicolantonio, F., Siena, S., Bardelli, A.

“…Monitoring response and resistance to kinase inhibitors is essential to precision cancer medicine, and is usually investigated by molecular profiling of a…”
Get full text

Final Results of the HERACLES trial in HER2 amplified colorectal cancer by Siena, S., Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Zagonel, V., Leone, F., Martinelli, E., Ciardiello, F., Racca, P., Amatu, A., Palmeri, L., Valtorta, E., Cassingena, A., Vanzulli, A., Regge, D., Veronese, S., Bardelli, A., Marsoni, S.

Get full text